Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

TERMINATED

S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma

Lead Sponsor:

SWOG Cancer Research Network

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Multiple Myeloma

Plasmacytoma

Eligibility:

All Genders

18-120 years

Phase:

PHASE2

Brief Summary

RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and fludeoxyglucose F 18 positron emission tomography (\^18FDG-PET) may help diagnose solitary plasmacytoma. PURPOSE: This c...

Detailed Description

OBJECTIVES: * Determine the proportion of patients who are misclassified as true solitary plasmacytoma by MRI and whole-body fludeoxyglucose F 18 positron emission tomography as a supplement to imagi...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed solitary plasmacytoma of 1 of the following types:
  • Solitary bone plasmacytoma
  • Extraosseus solitary plasmacytoma
  • Bone marrow plasmacytosis \< 10% within the past 4 weeks
  • Low serum and/or urine M-protein meeting ≥ 1 of the following criteria:
  • Serum IgG \< 3.5 g/dL
  • Serum IgA \< 2.0 g/dL
  • Urine M-protein (kappa or lambda) \< 1.0 g/24 hours
  • No lytic lesions on skeletal survey other than a single lesion associated with solitary plasmacytoma within the past 4 weeks
  • PATIENT CHARACTERISTICS:
  • Age
  • 18 and over
  • Performance status
  • Zubrod 0-2
  • Life expectancy
  • Not specified
  • Hematopoietic
  • Hemoglobin ≥ 10 g/dL\* AND/OR
  • No hemoglobin 2 g/dL \< lower limit of normal\* (LLN) NOTE: \*Patients with a history of hemoglobin \< 10 g/dL AND/OR \< 2 g/dL \< LLN that has corrected or improved after epoetin alfa but requires continued treatment with epoetin alfa are not eligible
  • Hepatic
  • Not specified
  • Renal
  • Calcium ≤ 10.5 mg/dL OR
  • Calcium normal
  • Creatinine ≤ 2 mg/dL
  • Other
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, or stage I or II cancer that is currently in complete remission
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • Not specified
  • Chemotherapy
  • Not specified
  • Endocrine therapy
  • No prior high-dose steroids except to relieve neurological compromise
  • Radiotherapy
  • Prior localized radiotherapy for myeloma allowed
  • Concurrent radiotherapy allowed
  • Surgery
  • Prior surgery for myeloma allowed
  • Other
  • No other prior therapy for myeloma
  • Concurrent enrollment in protocol SWOG-S0309 (Myeloma Specimen Repository) allowed

Exclusion

    Key Trial Info

    Start Date :

    April 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2007

    Estimated Enrollment :

    2 Patients enrolled

    Trial Details

    Trial ID

    NCT00109889

    Start Date

    April 1 2005

    End Date

    April 1 2007

    Last Update

    April 24 2017

    Active Locations (26)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 7 (26 locations)

    1

    Mobile Infirmary Medical Center

    Mobile, Alabama, United States, 36652-2144

    2

    Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

    Little Rock, Arkansas, United States, 72205

    3

    Tammy Walker Cancer Center at Salina Regional Health Center

    Salina, Kansas, United States, 67401

    4

    University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, United States, 48109-0942